Product Launches and Patent Expiries to Push Major Depressive
Disorder Treatment Market through Fluctuating Growth Period by 2023
The therapeutics market for Major Depressive Disorder (MDD) will face a dynamic
phase up until the end of 2023, thanks to the potential launch of new
treatments following the patent expirations of top-selling products, according
to new report.
The PharmaPoint: Major Depressive Disorder - Global Drug Forecast and Market
Analysis to 2023 report, the MDD treatment market achieved sales of
approximately $9.3 billion in 2013 across the seven major markets (7MM: the US,
France, Germany, Italy, Spain, the UK and Japan) and Australia. These sales
will witness minimal growth by the end of 2023, reaching an estimated $9.7
billion, at a Compound Annual Growth Rate (CAGR) of 0.39%.
However, The forecasts that the market value will first undergo a decline until
2017, with sales dropping to $7.3 billion. This can be attributed mainly to the
expirations of patents for Eli Lilly’s Cymbalta, Otsuka Pharmaceutical/BMS’
Abilify and AstraZeneca’s Seroquel XR.
The Senior Analyst covering Neurology, says: “Additionally, there are a number
of significant needs in the depression therapeutics market that are yet to be
addressed. These include the requirement for products that demonstrate improved
efficacy, more favorable safety profiles and a rapid onset of antidepressant
effects. Ample opportunity therefore exists for players looking to develop and
potentially introduce therapies, which can address these unmet needs, into this
arena.”
Publisher states that there are already seven products in the late-stage
pipeline that could enter the MDD market during the forecast period. These
include adjunctive therapies, such as Otsuka/Lundbeck’s brexpiprazole, Forest
(Actavis)/Gedeon Richter/Mitsubishi Tanabe Pharma’s cariprazine, Alkermes’s
ALKS-5461 and Naurex’s GLYX-13, along with antidepressant therapies, including
Euthymics Bioscience’s amitifadine, Lundbeck/Takeda’s tedatioxetine and
e-Therapeutics’ ETS6103.
The Senior Analyst continues: “All seven of these pipeline drugs show promise
as safer and more efficacious treatments for MDD patients, while GLYX-13 and ETS6103
in particular boast the potential to provide rapid antidepressant effects.
“With their ability to address some of the MDD treatment market’s key unmet
needs, we believe that these products’ launches could well spark its return to
growth in 2018. Other driving factors behind the reversal in its decline will
be the increasing uptake of Lundbeck/Takeda’s Brintellix, combined with the
expanding number of MDD prevalent cases that we expect to see by the end of
2023.”
PharmaPoint: Major Depressive Disorder - Global Drug Forecast and Market
Analysis to 2023 report provides an overview of Major Depressive Disorder
(MDD), including epidemiology, etiology, pathophysiology, symptoms, diagnosis
and current treatment options. The key topics covered include strategic
competitor assessment, market characterization, unmet needs and implications
for the MDD therapeutics market.
Know more about this report
at
– http://mrr.cm/Za3
To
browse more Pharma and Healthcare Reports visit:
About Market Research Reports, Inc.
Market
Research Reports, Inc. is the world's leading source for market research
reports and market data. We provide you with the latest market research reports
on global markets, key industries, leading companies, new products and latest
industry analysis & trends.
No comments:
Post a Comment
Note: only a member of this blog may post a comment.